（编辑 丛可心） 证券日报网讯 1月28日，奥飞娱乐发布公告称，公司预计2025年度归属于上市公司股东的净利润为6， 000万元至8，000万元，上年同期为-28，528.80万元，比上年同期增长121.03%至128.04%。 ...

Core Viewpoint - He Yuan Biotechnology (Shanghai) Co., Ltd. forecasts a net loss of between 237 million yuan and 195 million yuan for 2025, representing a reduction in losses by 84.81 million yuan to 127 million yuan compared to the previous year [1] Group 1: Company Performance - The company has been deeply engaged in the cell and gene therapy (CGT) field for over a decade, developing core technology clusters for vector development, production processes, and quality control [1] - As of the end of 2025, He Yuan has assisted clients in obtaining over 60 clinical trial approvals, with 14 approvals granted by the U.S. Food and Drug Administration [1] - The company has established a million-level cell bank with one-click access and full visual management, along with 14 fully automated production lines in the regenerative medicine sector [1] Group 2: Technological Advancements - Continuous investment in technology has created a differentiated competitive barrier for the company [2] - In 2025, He Yuan's viral vector upgrades, including the VPack packaging system and AAV-PANX products, are expected to achieve high production [2] - The company has introduced proprietary technologies in gene editing and nucleic acid delivery, including the micro-light gene Cas12 protein and LNP-mRNA delivery system licensing [2] Group 3: Industry Position - Analysts indicate that He Yuan, with its comprehensive service capabilities and scalable delivery systems, has secured a favorable position in the CGT industrialization process [2] - The company's ongoing investments in technology, production capacity, and ecosystem collaboration are expected to further solidify its industry-leading position and contribute to the long-term development of the cell and gene therapy sector [2]

Core Viewpoint - The company, Xianhui Technology, forecasts a significant increase in net profit for the year 2025, projecting a rise of 56.93% compared to the previous year [1] Financial Performance - The expected net profit attributable to the parent company's owners for 2025 is 350 million yuan [1] - This represents an increase of 126.9771 million yuan from the previous year's legally disclosed data [1]

Core Insights - The company, Orbbec, is focusing on 3D vision products utilizing MX series depth engine chips, which are ASIC/SoC chip solutions that offer superior computing performance, lower power consumption, and smaller size compared to FPGA chips [1] - The company has developed various 3D vision products and solutions for both consumer and industrial applications, including several 3D scanners in collaboration with Creality [1] - These 3D scanners meet the needs of end customers in areas such as 3D printing, industrial reverse engineering, cultural relic restoration, and game scene production [1] - The company aims to continuously monitor the development and application of innovative technology solutions to enhance product competitiveness and intrinsic value [1]

Group 1 - The company, Zhongfu Shenying, announced an expected annual revenue for 2025 between 210,000 million yuan and 230,000 million yuan, representing a year-on-year growth of 34.85% to 47.69% [1] - The company anticipates achieving a net profit attributable to the parent company of between 8,000 million yuan and 12,000 million yuan, indicating a turnaround from losses to profitability [1]

（编辑 王雪儿） 证券日报网讯 1月28日，晶晨股份在互动平台回答投资者提问时表示，公司与谷歌拥有十余年的深度合 作基础，是谷歌新一代端侧AI硬件（整合Gemini AI）相关产品的核心芯片供应商。双方在人工智能领 域协同聚焦于谷歌端侧大模型Gemini的硬件生态落地，相关合作成果已在2025年第三季度报告中披露。 公司推出了适配Gemini的智能音箱、智能可视化门铃、室内及室外智能摄像头等多款新产品，助力谷歌 的智能家居产品整体向内嵌端侧大模型能力的新一代产品升级，进一步激活存量市场需求。当前端侧智 能技术渗透率持续提升，正不断催生新的应用形态与场景，公司也将持续挖掘端侧智能的应用潜力。 ...

（编辑 王雪儿） 证券日报网讯 1月28日，兴图新科在互动平台回答投资者提问时表示，公司核心视频高压缩技术可在画 质无损前提下实现90%存储容量缩减，相关超存引擎产品序列可在不更换现有系统、设备和不增加硬盘 的情况下，实现4-10倍近无损压缩，综合存储成本降低50%以上，可有效对冲存储设备涨价压力。具体 产品包括超存引擎（32路-1500路）、DPU零载加速卡和超存智算一体机等。公司联合长江计算、神州 数码、中国移动、中国电信打造存储解决方案和产品，可广泛适配华为、中兴、长江计算、超聚变、同 泰怡、攀升等品牌服务器。 ...

Core Viewpoint - The company Jin Cheng Xin has disclosed its current guarantee usage and related financial metrics, indicating a significant portion of its net assets are tied up in guarantees [1] Group 1: Guarantee Usage - As of the announcement date, the total guarantee amount used by the company is 296,680.33 million RMB, which accounts for 33.02% of the company's most recent audited net assets attributable to shareholders [1] - The actual guarantees being executed amount to approximately 292,527.00 million RMB, representing 32.56% of the company's most recent audited net assets attributable to shareholders [1] - Within the annual guarantee limit, the actual guarantees being executed are about 107,742.87 million RMB [1] Group 2: Financial Health - The company has reported no overdue guarantee matters as of the announcement date, indicating a stable financial position regarding its guarantees [1]

证券日报网讯 1月28日，捷昌驱动发布公告称，截至本公告日，公司及子公司经审批的担保总额为人民 币12亿元，占公司最近一期经审计归属上市公司股东净资产的比例为27.76%；公司及子公司已签署担 保合同且尚在履行中的担保总额为人民币8.17亿元（含本次），占公司最近一期经审计归属上市公司股 东的净资产比例为18.91%。上述担保均为公司及子公司对合并报表范围内全资子公司的担保，公司不 存在对合并报表范围外的主体提供担保的情况。公司无逾期担保事项。 （编辑 袁冠琳） ...

Core Viewpoint - The company emphasizes the integration of artificial intelligence (AI) technology with the entire traditional Chinese medicine (TCM) industry chain, aiming for intelligent upgrades and high-quality development through AI applications in various core processes [1] Group 1: AI Integration in Operations - The company has developed the world's largest Ganoderma lucidum germplasm information database, utilizing digital breeding simulations and automated phenotype data collection for precise breeding, transitioning from experimental to data-driven biological breeding [1] - AI predictive models and image recognition technologies are employed to create smart farms, enabling precise control of the growth environment for medicinal materials and intelligent quality inspection [1] - The company has independently developed a customer service Q&A robot based on customized large models, establishing an AI dynamic knowledge engine to optimize operational processes and reduce labor costs [1] Group 2: Market and Consumer Insights - AI technology is used to analyze multi-channel data, constructing user profiles based on age, physical condition, and consumption preferences, which aids in precise advertising and personalized product recommendations [1] - The company plans to continue deepening the integration of "AI + TCM" innovation, further promoting intelligent upgrades across the entire industry chain [1]